P49368 (TCPG_HUMAN) Homo sapiens (Human)
T-complex protein 1 subunit gamma UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
However, an attempt to improve models for this target was made on 2025-04-30. The outcome - failed for technical reasons.
Available Structures
50 Experimental Structures
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound |
Heteromer P17987; P40227; P48643; P50990; P50991; P63261; P78371; Q99832; Q9H2J4; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 10 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 8 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 0 |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 7 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 9 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 15 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 5 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 6 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex close state 11 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 13 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 12 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 14 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 1 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 3 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex best PhLP1 class |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 4 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 2 |
Heteromer O14775; P17987; P40227; P48643; P50990; P50991; P78371; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
cryo-EM structure of human TRiC-ATP-closed state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | ||||
Human TRiC-tubulin-S3 |
Heteromer P07437; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
cryo-EM structure of human TRiC-ADP-AlFx |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC-PhLP2A complex in the closed state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; Q9H2J4; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate I |
Heteromer P07437; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
Human TRiC complex in closed state with nanobody bound (Consensus Map) |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate II |
Heteromer P07437; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 8×AF3; 8×MG; 8×ADP; | |||
Human TRiC complex in closed state with nanobody and tubulin bound |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q13885; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate III |
Heteromer P07437; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
Human TRiC-PhLP2A-actin complex in the closed state |
Heteromer P17987; P40227; P48643; P50990; P50991; P60709; P78371; Q99832; Q9H2J4; | 100 | ||||
The beta-tubulin folding intermediate IV |
Heteromer P07437; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
Human TRiC in ATP/AlFx closed state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | ||||
Human TRiC/CCT complex with reovirus outer capsid protein sigma-3 |
Heteromer P03527; P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 1×ZN; | |||
hTRiC-hPFD Class6 |
Heteromer O15212; O60925; P17987; P40227; P48643; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class4 |
Heteromer O15212; O60925; P17987; P40227; P48643; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class5 |
Heteromer O15212; O60925; P17987; P40227; P48643; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class1 (No PFD) |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | ||||
hTRiC-hPFD Class2 |
Heteromer O15212; O60925; P17987; P40227; P48643; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class3 |
Heteromer O15212; O60925; P17987; P40227; P48643; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
Human TRiC open state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100.0 | 6×ADP; | |||
Cryo-EM structure of human TRiC-tubulin-S2 |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ATP; | |||
cryo-EM structure of human TRiC-ADP |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | 16×ADP; | |||
Cryo-EM structure of Human TRiC-ATP-open state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | ||||
Cryo-EM structure of human TRiC-NPP state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100 | ||||
Open state CCT-G beta 5 complex |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100.0 | 16×ADP; | |||
Human TRiC complex in open state with nanobody bound |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100.0 | 16×MG; 16×ADP; 12×AF3; | |||
CCT G beta 5 complex intermediate state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100.0 | 16×ADP; | |||
Human CCT:mLST8 complex |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100.0 | 2×ADP; | |||
Human TRiC-PhLP2A complex in the open state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; Q9H2J4; | 100 | 10×ADP; | |||
Cryo-EM structure of human TRiC-tubulin-S1 state |
Heteromer P17987; P40227; P48643; P50990; P50991; P78371; Q99832; | 100.0 | 6×ADP; | |||
Prefoldin-tubulin-TRiC complex |
Heteromer O15212; O60925; P17987; P40227; P48643; P50990; P50991; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | 4×ADP; | |||
The focused refinement of CCT3-PhLP2A from TRiC-PhLP2A complex in the open state |
Heteromer Q9H2J4; | 100 | 1×ADP; | |||
1 SWISS-MODEL model
Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7nvm.1.E | monomer | 0.75 | 1×ADP; 1×MG; 1×AF3; | 100.00 | ||
1 SWISS-MODEL model built on isoform sequence
Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|---|
Isoform 2 | 7nvm.1.E | monomer | 0.77 | 1×MG; | 100.00 | ||